ECE2023 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (355 abstracts)
Leptin reduces the risk of poor glycemic control in type two diabetes mellitus patients on metformin therapy
Mahmoud A. Alfaqih 1 , Mukhallad Aljanabi 2 , Ebaa Ababneh 2 , Mariam Khanfar 2 & Mai Sater 1
1Arabian Gulf University, Medical Biochemistry, Manama, Bahrain; 2Jordan University of Science and Technology, Physiology and Biochemistry, Irbid, Jordan
Purpose: Type two diabetes mellitus (T2DM) is a chronic disease of debilitating complications. Good glycemic control could delay disease progression and microvascular complications. Nonetheless, some patients cannot maintain glycemic control.
Patients and Methods: We recruited 340 T2DM patients on metformin therapy and categorized them according to their HbA1c levels into patients with good vs poor glycemic control. The levels of serum leptin were measured. Patients were genotyped for the following SNPs in the LEP gene (rs7799039, rs2167270 and rs791620).
Results: Serum leptin reduced the risk of poor glycemic control following adjustments with age, gender, BMI, treatment duration and HOMA-IR (OR= 0.984; CI: 0.973 - 0.994; P=0.002). The GA genotype of rs2167270 was less frequent in patients with poor glycemic control and reduced its risk in multivariate analysis (OR= 0.428; CI: 0.248 - 0.737; P=0.002).
Conclusion: These findings suggest that leptin therapy or strategies that re-sensitize tissues to existing leptin could be utilized for better glycemic control in T2DM patients on metformin.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more